5 news items
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
be accessed under "Publications and Presentations" in the Investor section of the Company's website
Karyopharm to Participate at the Jefferies Global Healthcare Conference
KPTI
29 May 24
with accompanying slides, can be accessed under "Events & Presentations
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI
8 May 24
quarter 2024 financial results, the transactions described herein and other company updates. To access the conference call, please dial (800) 836-8184
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
Time, to discuss the first quarter 2024 financial results and provide business highlights. To access the conference call, please dial (800) 836
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
KPTI
2 May 24
.
To access
- Prev
- 1
- Next